---

Market Overview

---

The global cell-based assay market is projected to reach $38.23 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.44% during the forecast period from 2023 to 2032.

A cell-based assay is a laboratory technique that utilizes cultured living cells to analyze and evaluate various biochemical or cellular processes. It provides valuable insights into parameters such as cell motility, toxicity, proliferation, and morphology, allowing researchers to study how cells respond to specific experimental conditions. This technique is particularly relevant in drug discovery, diagnostics, and the production of quantifiable products. Cell-based assays are often used in conjunction with corresponding gene assays to enhance sensitivity and signal amplification of cell-signaling cascades, making them suitable for miniaturization.

According to latest Research, the cell-based assay market is a global industry dedicated to the creation, manufacturing, and dissemination of laboratory tests that utilize living cells to detect, quantify, and analyze biological processes or substances. This market encompasses a wide range of techniques and technologies, including high-throughput screening, 3D cell culture, and stem cell research. The cell-based assay market is rapidly expanding within the life sciences industry, driven by the increasing demand for more precise, reliable, and effective methods in drug discovery, toxicity testing, and disease modeling.

Cell-based assays have revolutionized modern research and applications by providing a powerful and versatile tool for studying cellular behavior, drug efficacy, and toxicity in a controlled laboratory environment. These assays involve the use of living cells to assess cellular responses to various stimuli, enabling scientists to investigate cellular processes, signaling pathways, and molecular interactions. They have become indispensable in fields such as cancer research, drug discovery, toxicology studies, and regenerative medicine, accelerating scientific discovery and advancing medical research and applications.

The anticipated growth of the global cell-based assay market in the forecast period is largely driven by the promise of breakthroughs beyond drug discovery. Cell-based assays provide a more comprehensive representation of biological systems compared to basic biochemical assays, as they encompass all the organelles of a cell functioning as a single entity, rather than just isolated receptors or enzymes.

The impact analysis for the market’s drivers, restraints, and opportunities has been evaluated both in the short-term (2022-2026) and long-term (2027-2032). Key developments and strategies undertaken by key players in the market have been considered to assess the future scope of integrating advancing technologies for superior outcomes.

The cell-based assay market has also been influenced by the COVID-19 pandemic. Research and development efforts to create vaccines and treatments for the SARS-CoV-2 virus have intensified, and the availability of research funding and demand for cell-based test products are expected to expand. Companies in the industry are adapting their growth strategies to capitalize on opportunities in COVID-19 research by introducing innovative products for viral infection research, vaccine development, and drug discovery.

In conclusion, the global cell-based assay market is expected to experience significant growth driven by the demand for precise and effective methods in drug discovery, toxicity testing, and disease modeling. Cell-based assays have transformed research and applications by providing valuable insights into cellular behavior and mechanisms. The impact of COVID-19 has further accelerated the growth of this market, with increased research activities and the need for COVID-19-related tests and treatments. However, challenges related to cost and lack of standardization may limit market growth.

---

Market Segmentation

---

The market is segmented based on various factors, including product, application, technology, end user, and region.

Segmentation by Product
Consumables
Instruments and Software
Services

Segmentation by Application
Drug Screening
Basic Research
Predictive Toxicology
Other Applications (Other Industries, Cell and Gene therapy, among others)

Segmentation by Technology
Flow Cytometry
Automated Handling
High Throughput Screening
High Content Screening
Other Technologies (Label-Free Detection, Image Cytometry, among others)

Segmentation by End User
Pharmaceutical and Biopharmaceutical Companies
Contract Research Organizations (CROs)
Academic and Research Institutes
Other End Users (Government Organizations)

Segmentation by Region
North America
Europe
Asia-Pacific
Rest-of-the-World

The global cell-based assay market is categorized into consumables, instruments and software, and services based on product type. Consumables are essential components of cell-based assays as they directly impact the accuracy, precision, and reproducibility of experimental results. Laboratory consumables are used for a limited time and then discarded after depletion. Examples of consumables include assay kits, reagents, cell lines, microplates, probes, and labels. The market for cell-based assays has several key players that supply reagents, assay kits, solvents, and other consumables. Consumables have the highest demand globally due to their frequent usage.

As of 2022, drug screening applications dominated the cell-based assay market with a 41.27% market share. Cell-based drug screening assays have become crucial in drug discovery research, helping identify potential lead compounds from large chemical compound libraries. Advanced microscopy techniques, such as high-content screening (HCS), have been integrated to enhance the efficacy of these assays. HCS allows for the simultaneous measurement of various properties of individual cells, including reporter signals, morphological analysis, and phenotypic profiling. HCS is a form of high-throughput screening (HTS) that utilizes automated imaging and data analysis to generate large-scale datasets suitable for drug discovery. HTS assays are robust, highly sensitive, and can be miniaturized, enabling rapid testing of large libraries.

Flow cytometry dominated the cell-based assay market by technology in 2022, with a 34.11% market share. Flow cytometry is a robust technique used for comprehensive analysis and characterization of cells in cell-based assays. It involves an automated instrument called a flow cytometer that measures various properties of cells individually as they pass through a laser beam. Flow cytometry enables high-throughput analysis of large cell populations, providing quantitative and qualitative data on cell size, complexity, viability, and surface markers. One application of flow cytometry is cell sorting, which accurately separates specific cell populations based on their characteristics, allowing for further analysis or experimentation.

The pharmaceutical and biopharmaceutical companies segment dominated the cell-based assay market by end user in 2022, holding a 51.36% market share. Cell-based assays play a crucial role in drug research and development, driven by pharmaceutical and biopharmaceutical companies. These assays are used to explore the effects of potential drugs on living cells during the initial stages of drug development, such as target identification, efficacy evaluation, and toxicity and safety assessment. Pharmaceutical and biopharmaceutical companies utilize cell-based assays to screen substances, refine lead candidates, and assess the safety and effectiveness of potential medications. They may also employ cell-based tests for production and quality control purposes, such as checking for impurities or pollutants.

In 2022, North America dominated the global cell-based assay market and is expected to maintain its dominance throughout the forecast period of 2023-2032. However, the Asia-Pacific (APAC) region, which includes several emerging economies, is projected to exhibit the highest compound annual growth rate (CAGR) of 9.53% during the forecast period of 2023-2032.

---

Competitive Landscape

---

Key companies profiled in this report include Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Danaher Corporation, Merck KGaA, Thermo Fisher Scientific, Inc., Corning Incorporated, Lonza Group AG, Agilent Technologies, Inc., Promega Corporation, PerkinElmer, Inc., Eurofins DiscoverX Products, Cell Signaling Technology, Inc., Charles River Laboratories International, Inc., Laboratory Corporation of America Holdings.

---

Recent Industry Developments

---

Lonza Group AG announced in April 2022 that it has made improvements to its automated cell therapy manufacturing system, the Cocoon Platform. The latest addition, known as magnetic selection, expands the capabilities of the platform by enabling cell binding, separation, and, if necessary, bead removal, all done through the Cocoon cassette.

In April 2020, Bio-Rad Laboratories, Inc. successfully acquired Celsee, Inc., a company that offers instruments and consumables for the isolation, detection, and analysis of individual cells.

PerkinElmer, Inc. announced in July 2021 that it had entered into a definitive agreement to acquire BioLegend for $5.25 billion. BioLegend is a manufacturer of high-quality antibodies and reagents used in biomedical research.

Lonza Group AG and Junshi Biosciences expanded their collaboration in April 2021 to focus on the development and manufacturing of biologics. Lonza Group AG will leverage its global network and local expertise to assist Junshi Biosciences in accelerating the development of drugs in its pipeline and increasing their global market adoption. Under the agreement, Lonza Group AG will provide comprehensive support, including cell line creation and development, supply of cell culture media and reagents, process development, and GMP manufacturing.

Lonza Group AG and CN Bio established a distribution agreement in July 2021. As part of this collaboration, Lonza Group AG will provide hepatic cells to CN Bio for prequalification, which will be utilized in their PhysioMimix single- and multi-organ MPS technology. This partnership aims to revolutionize the generation of preclinical data that is more relevant to humans. By using prequalified cells, customers can save time and ensure the discovery of cells that will grow and function effectively in 3D culture without the need for experimenting with multiple cell types.

---

Key Questions Answered

---

What is the definition of cell-based assays?

What is the current market size of cell-based assays and what is their future potential?

How has the COVID-19 pandemic impacted the cell-based assay market?

What is the projected revenue for the global cell-based assay market?

Which geographical region is expected to contribute the highest revenue to the global cell-based assay market during the forecast period?

What are the major drivers, challenges, and opportunities in the global cell-based assay market and how do they affect the market?

What strategies have the major players implemented to maintain competitiveness in the market?

How will each segment of the market grow from 2022 to 2032?

Who are the leading players in the global cell-based assay market and what is their expected market dominance?